A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics

European Journal of Pharmaceutical Sciences

Volumn 48, Issue 3, 2013, Pages 416-427

  Steichen, Stephanie D ^a   Caldorera Moore, Mary ^a   Peppas, Nicholas A ^a  

^a The University of Texas at Austin   (United States)

Author keywords

Cancer; Chemotherapy; Liposomes; Micelles; Nanoparticles; Nanosphere

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DAUNORUBICIN; DENDRIMER; DOCETAXEL; DOXORUBICIN; FOLIC ACID; GEMTUZUMAB; HYALURONIC ACID; IBRITUMOMAB TIUXETAN; IPILIMUMAB; LIPOSOME; NANOCAPSULE; NANOCARRIER; NANOSPHERE; OFATUMUMAB; PACLITAXEL; PANITUMUMAB; PROTEOGLYCAN; RITUXIMAB; TRANSFERRIN; TRASTUZUMAB; DELAYED RELEASE FORMULATION; NANOPARTICLE;

CANCER CHEMOTHERAPY; CARDIOTOXICITY; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; EXTRACELLULAR MATRIX; FATIGUE; FIRST PASS EFFECT; GLOMERULUS CAPILLARY; GLOMERULUS FILTRATION; HUMAN; INTRACELLULAR TRANSPORT; LIPID BILAYER; LYMPHATIC SYSTEM; MACROPHAGE; MICELLE; MONONUCLEAR PHAGOCYTIC SYSTEM; NAUSEA; PARTICLE SIZE; PHAGOCYTOSIS; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; SURFACE PROPERTY; TISSUE PRESSURE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ADMINISTRATION AND DOSAGE; BIOLOGICAL MODEL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOPHYSIOLOGY; PHARMACOKINETICS; THERAPEUTIC USE; TISSUE DISTRIBUTION; TRENDS; VASCULARIZATION;

ANTINEOPLASTIC AGENTS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; NANOPARTICLES; NEOPLASMS; TISSUE DISTRIBUTION; TUMOR MICROENVIRONMENT;

EID: 84872401360     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2012.12.006     Document Type: Review

References (79)

1. Adams, G.P., Weiner, L.M., 2005. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23, 1147-1157.
2. Alexis, F., Pridgen, E., Molnar, L.K., Farokhzad, O.C., 2008. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharmac. 5, 505-515.
3. Baban, D.F., Seymour, L.W., 1998. Control of tumour vascular permeability. Adv. Drug Deliv. Rev. 34, 109-119.
4. Boulikas, T., Vougiouka, M., 2003. Cisplatin and platinum drugs at the molecular level. (Review). Oncol. Rep. 10, 1663-1682.
5. Brannon-Peppas, L., Blanchette, J.O., 2004. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56, 1649-1659.
6. Brigger, I.N., Dubernet, C., Couvreur, P., 2002. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631-651.
7. Brissette, R., Prendergast, J., Goldstein, N., 2006. Identification of cancer targets and therapeutics using phage display. Curr. Opin. Drug Discov. Devel. 9, 363-369.
8. Brooks, P.C., Montgomery, A.M.P., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier, G., Cheresh, D.A., 1994. Integrin αvÎ23 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164.
9. Brown, J.M., Giaccia, A.J., 1998. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 58, 1408-1416.
10. Byrne, J.D., Betancourt, T., Brannon-Peppas, L., 2008. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 60, 1615-1626.
11. Caldorera-Moore, M., Guimard, N., Shi, L., Roy, K., 2010. Designer nanoparticles: Incorporating size, shape and triggered release into nanoscale drug carriers. Expert. Opin. Drug Deliv. 7, 479-495.
12. Caldorera-Moore, M., Kang, M.K., Moore, Z., Singh, V., Sreenivasan, S.V., Shi, L., Huang, R., Roy, K., 2011a. Swelling behavior of nanoscale, shape-and sizespecific, hydrogel particles fabricated using imprint lithography. Soft Matter 7, 2879-2887.
13. Caldorera-Moore, M., Liechty, W.B., Peppas, N.A., 2011b. Responsive theranostic systems: Integration of diagnostic imaging agents and responsive controlled release drug delivery carriers. Acc. Chem. Res. 44, 1061-1070.
14. Caldorera-Moore, M., Peppas, N.A., 2009. Micro-and nanotechnologies for intelligent and responsive biomaterial-based medical systems. Adv. Drug Deliv. Rev. 61, 1391-1401.
15. Champion, J.A., Katare, Y.K., Mitragotri, S., 2007. Making polymeric micro-and nanoparticles of complex shapes. Proc. Natl. Acad. Sci. USA 104, 11901-11904.
16. Chithrani, B.D., Chan, W.C.W., 2007. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. Nano Lett. 7, 1542-1550.
17. Davis, M.E., Chen, Z., Shin, D.M., 2008. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771-782.
18. Dellian, M., Witwer, B.P., Salehi, H.A., Yuan, F., Jain, R.K., 1996. Quantitation and physiological characterization of angiogenic vessels in mice. Effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am. J. Pathol. 149, 59-71.
19. Dhar, S., Gu, F.X., Langer, R., Farokhzad, O.C., Lippard, S.J., 2008. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGAâ€"PEG nanoparticles. Proc. Natl. Acad. Sci. USA 105, 17356-17361.
20. Dreher, M.R., Liu, W., Michelich, C.R., Dewhirst, M.W., Yuan, F., Chilkoti, A., 2006. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J. Natl. Cancer Inst. 98, 335-344.
21. Duncan, R., 2003. The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2, 347-360.
22. Fang, C., Shi, B., Pei, Y.-Y., Hong, M.-H., Wu, J., Chen, H.-Z., 2006. In vivo tumor targeting of tumor necrosis factor-α-loaded stealth nanoparticles: Effect of MePEG molecular weight and particle size. Eur. J. Pharm. Sci. 27, 27-36.
23. Feng, S.-S., Chien, S., 2003. Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem. Eng. Sci. 58, 4087-4114.
24. Glangchai, L.C., Caldorera-Moore, M., Shi, L., Roy, K., 2008. Nanoimprint lithography based fabrication of shape-specific, enzymatically-triggered smart nanoparticles. J. Control. Release 125, 263-272.
25. Gratton, S.E.A., Ropp, P.A., Pohlhaus, P.D., Luft, J.C., Madden, V.J., Napier, M.E., DeSimone, J.M., 2008. The effect of particle design on cellular internalization pathways. Proc. Natl. Acad. Sci. USA 105, 11613-11618.
26. Gu, F.X., Karnik, R., Wang, A.Z., Alexis, F., Levy-Nissenbaum, E., Hong, S., Langer, R.S., Farokhzad, O.C., 2007. Targeted nanoparticles for cancer therapy. Nano Today 2, 14-21.
27. Haley, B., Frenkel, E., 2008. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol. 26, 57-64.
28. Hilgenbrink, A.R., Low, P.S., 2005. Folate receptor-mediated drug targeting: From therapeutics to diagnostics. J. Pharm. Sci. 94, 2135-2146.
29. Hoffmann, T., Hafner, D., Ballo, H., Haas, I., Bier, H., 1997. Antitumor activity of antiepidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res. 17, 4419-4425.
30. Hori, K., Suzuki, M., Tanda, S., Saito, S., 1991. Characterization of heterogeneous distribution of tumor blood flow in the rat. Cancer Sci. 82, 109-117.
31. Hughes, G.A., 2005. Nanostructure-mediated drug delivery. Nanomedicine 1, 22-30.
32. Hurley, L.H., 2002. DNA and its associated processes as targets for cancer therapy. Nat. Rev. Cancer 2, 188-200.
33. Jain, R.K., 1987. Transport of molecules in the tumor interstitium: A review. Cancer Res. 47, 3039-3051.
34. Jain, R.K., 1998. Delivery of molecular and cellular medicine to solid tumors. J. Control. Release 53, 49-67.
35. Jang, S.H., Wientjes, M.G., Lu, D., Au, J.L.S., 2003. Drug delivery and transport to solid tumors. Pharm. Res. 20, 1337-1350.
36. Janson, C.G., During, M.J., Liang, K.W., Liu, F., Huang, L., 2006. Targeted Gene Delivery Peptide Nucleic Acids, Morpholinos and Related Antisense Biomolecules. Springer, US, pp. 30-37.
37. Johnston, A.P.R., Kamphuis, M.M.J., Such, G.K., Scott, A.M., Nice, E.C., Heath, J.K., Caruso, F., 2012. Targeting cancer cells: Controlling the binding and internalization of antibody-functionalized capsules. ACS Nano.
38. Jones, A., Harris, A.L., 1998. New developments in angiogenesis: A major mechanism for tumor growth and target for therapy. Cancer J. Sci. Am. 4, 209-217.
39. Krag, D.N., Shukla, G.S., Shen, G.-P., Pero, S., Ashikaga, T., Fuller, S., Weaver, D.L., Burdette-Radoux, S., Thomas, C., 2006. Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Res. 66, 7724-7733.
40. Kwon, G.S., Kataoka, K., 1995. Block copolymer micelles as long-circulating drug vehicles. Adv. Drug Deliv. Rev. 16, 295-309.
41. Lasic, D.D., 1998. Novel applications of liposomes. Trends Biotechnol. 16, 307-321.
42. Lavasanifar, A., Samuel, J., Kwon, G.S., 2002. Poly(ethylene oxide)-block-poly(lamino acid) micelles for drug delivery. Adv. Drug Deliv. Rev. 54, 169-190.
43. Liechty, W.B., Caldorera-Moore, M., Phillips, M.A., Schoener, C.A., Peppas, N.A., 2011. Advanced molecular design of biopolymers for transmucosal and intracellular delivery of chemotherapeutic agents and biological therapeutics. J. Control. Release 155, 119-127.
44. Liechty, W.B., Peppas, N.A., 2012. Expert opinion: Responsive polymer nanoparticles in cancer therapy. Eur. J. Pharm. Biopharm. 80, 241-246.
45. Maeda, H., 2001. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv. Biol. Regul. 41, 189-207.
46. Majoros, I.N.J., Myc, A., Thomas, T., Mehta, C.B., Baker, J.R., 2006. PAMAM dendrimerbased multifunctional conjugate for cancer therapy: Synthesis, characterization, and functionality. Biomacromolecules 7, 572-579.
47. Matsumura, Y., Kimura, M., Yamamoto, T., Maeda, H., 1988. Involvement of the Kinin-generating cascade in enhanced vascular permeability in tumor tissue. Cancer Sci. 79, 1327-1334.
48. Mehren, M.v., Adams, G.P., Weiner, L.M., 2003. Monoclonal antibody therapy for cancer. Annu. Rev. Med. 54, 343-369.
49. Mendelsohn, J., 1997. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res. 3, 2703-2707.
50. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L., 2004. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185-229.
51. Moghimi, S.M., Hedeman, H., Christy, N.M., Illum, L., Davis, S.S., 1993. Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats. J. Leukocyte Biol. 54, 513-517.
52. Nasongkla, N., Shuai, X., Ai, H., Weinberg, B.D., Pink, J., Boothman, D.A., Gao, J., 2004. CRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew. Chem., Int. Ed. 116, 6483-6487.
53. Nobs, L., Buchegger, F., Gurny, R., Allemann, E., 2005. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjugate Chem. 17, 139-145.
54. Owens, D.E., Peppas, N.A., 2006. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307, 93-102.
55. Park, K., Lee, S., Kang, E., Kim, K., Choi, K., Kwon, I.C., 2009. New generation of multifunctional nanoparticles for cancer imaging and therapy. Adv. Funct. Mater. 19, 1553-1566.
56. Peppas, N.A., Slaughter, B.V., Kanzelberger, M.A., 2012. Hydrogels in Polymer Science. A Comprehensive Reference. Elsevier, Amsterdam.
57. Phillips, M.A., Gran, M.L., Peppas, N.A., 2010. Targeted nanodelivery of drugs and diagnostics. Nano Today 5, 143-159.
58. Ponka, P., Lok, C.N., 1999. The transferrin receptor: Role in health and disease. Int. J. Biochem. Cell Biol. 31, 1111-1137.
59. Ratner, B.D., Hoffman, A.S., Schoen, F.J., 2004a. Biomaterials Science: An Introduction to Materials in Medicine, second ed. Elsevier Academic Press, San Diego.
60. Ratner, B.D., Hoffman, A.S., Schoen, F.J., Lemons, J.E., 2004b. Biomaterials Science. An Introduction to Materials in Medicine, second ed. Elsevier Academic Press, San Diego.
61. Roberts, W.G., Palade, G.E., 1995. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci. 108, 2369-2379.
62. Rolland, J.P., Maynor, B.W., Euliss, L.E., Exner, A.E., Denison, G.M., DeSimone, J.M., 2005. Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J. Am. Chem. Soc. 127, 10096-10100.
63. Rowinsky, M., Eric, K., 1997. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 48, 353-374.
64. Sahoo, S.K., Labhasetwar, V., 2005. Enhanced antiproliferative activity of transferrinconjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol. Pharmac. 2, 373-383.
65. Sahoo, S.K., Ma, W., Labhasetwar, V., 2004. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int. J. Cancer 112, 335-340.
66. Schoener, C.A., Hutson, H.N., Peppas, N.A., 2012. PH-responsive hydrogels with dispersed hydrophobic nanoparticles for the delivery of hydrophobic therapeutic agents. Polym. Int. 61, 874-879.
67. Stella, B., Arpicco, S., Peracchia, M.T., Desmaële, D., Hoebeke, J., Renoir, M., D'Angelo, J., Cattel, L., Couvreur, P., 2000. Design of folic acid-conjugated nanoparticles for drug targeting. J. Pharm. Sci. 89, 1452-1464.
68. Storm, G., Belliot, S.O., Daemen, T., Lasic, D.D., 1995. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev. 17, 31-48.
69. Sudimack, J., Lee, R.J., 2000. Targeted drug delivery via the folate receptor. Adv. Drug Deliv. Rev. 41, 147-162.
70. Venturoli, D., Rippe, B., 2005. Ficoll and dextran vs. globular proteins as probes for testing glomerular permselectivity: Effects of molecular size, shape, charge, and deformability. Am. J. Physiol. Renal Physiol. 288, F605-F613.
71. Wang, X., Yang, L., Chen, Z., Shin, D.M., 2008. Application of nanotechnology in cancer therapy and imaging. CA Cancer J. Clin. 58, 97-110.
72. Weber, J., 2007. Review: AntiCTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events. Oncologist 12, 864-872.
73. Weiner, L.M., Adams, G.P., 2000. New approaches to antibody therapy. Oncogene 19, 6144-6151.
74. Weiner, L.M., Surana, R., Wang, S., 2010. Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10, 317-327.
75. Weiss, R.B., 1992. The anthracyclines: Will we ever find a better doxorubicin? Semin. Oncol. 19, 670-686.
76. Wilson, D.S., Szostak, J.W., 1999. In vitro selection of functional nucleic acids. Annu. Rev. Biochem. 68, 611-647.
77. Wu, J., Akaike, T., Maeda, H., 1998. Modulation of enhanced vascular permeability in tumors by a Bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 58, 159-165.
78. Xin, H., Jiang, X., Gu, J., Sha, X., Chen, L., Law, K., Chen, Y., Wang, X., Jiang, Y., Fang, X., 2011. Angiopep-conjugated poly(ethylene glycol)-co-poly(e-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 32, 4293-4305.
79. Yoo, H.S., Park, T.G., 2004. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Control. Release 96, 273-283.